1. Home
  2. SNGX vs AMBO Comparison

SNGX vs AMBO Comparison

Compare SNGX & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • AMBO
  • Stock Information
  • Founded
  • SNGX 1987
  • AMBO 2000
  • Country
  • SNGX United States
  • AMBO United States
  • Employees
  • SNGX N/A
  • AMBO 163
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • AMBO Other Consumer Services
  • Sector
  • SNGX Health Care
  • AMBO Real Estate
  • Exchange
  • SNGX Nasdaq
  • AMBO Nasdaq
  • Market Cap
  • SNGX 6.5M
  • AMBO 7.0M
  • IPO Year
  • SNGX 1987
  • AMBO 2010
  • Fundamental
  • Price
  • SNGX $1.28
  • AMBO $2.95
  • Analyst Decision
  • SNGX
  • AMBO
  • Analyst Count
  • SNGX 0
  • AMBO 0
  • Target Price
  • SNGX N/A
  • AMBO N/A
  • AVG Volume (30 Days)
  • SNGX 2.7M
  • AMBO 10.7K
  • Earning Date
  • SNGX 08-08-2025
  • AMBO 01-01-0001
  • Dividend Yield
  • SNGX N/A
  • AMBO N/A
  • EPS Growth
  • SNGX N/A
  • AMBO N/A
  • EPS
  • SNGX N/A
  • AMBO 0.11
  • Revenue
  • SNGX $2,342.00
  • AMBO $9,392,000.00
  • Revenue This Year
  • SNGX N/A
  • AMBO N/A
  • Revenue Next Year
  • SNGX N/A
  • AMBO N/A
  • P/E Ratio
  • SNGX N/A
  • AMBO $27.78
  • Revenue Growth
  • SNGX N/A
  • AMBO 2.50
  • 52 Week Low
  • SNGX $1.09
  • AMBO $1.00
  • 52 Week High
  • SNGX $8.55
  • AMBO $5.55
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 34.55
  • AMBO 60.08
  • Support Level
  • SNGX $1.09
  • AMBO $2.25
  • Resistance Level
  • SNGX $1.88
  • AMBO $2.70
  • Average True Range (ATR)
  • SNGX 0.14
  • AMBO 0.29
  • MACD
  • SNGX -0.01
  • AMBO 0.08
  • Stochastic Oscillator
  • SNGX 22.78
  • AMBO 72.97

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About AMBO Ambow Education Holding Ltd.

Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.

Share on Social Networks: